The Northern Ireland Precision Biomarkers and Therapeutics consortium (NIPBT) is a partnership of Life and Health Science companies, Health Innovation Research Alliance Northern Ireland (HIRANI), Ulster University and Queen’s University Belfast which is strategically aligned with the research and economic development strategies of the Departments of Health (DoH) and Economy (DfE) of the devolved government. 

Our partners cover all aspects of a precision medicine drug/diagnostic development pipeline. The consortium is supported by a wider Life Science eco-system across NI encompassing over 363 companies as well the Institute for Research Excellence in Advanced Clinical Healthcare, (i-REACH) the Centre for Digital Health Care Technology (CDHT); and the Global Innovation Institute (GII).

Our mission

Our mission is to galvanise Northern Ireland’s strengths in digital health and pharmaceutical development through a shared strategic vision that will expand research capacity, drive innovation and maximise productivity​ resulting in the development of new technologies, diagnostics and therapeutics for the advancement of healthcare.  

Our Objectives

  • Integration: create a R&D hub that seeds and fosters collaboration, synergies and innovation.
  • Capacity Building: further develop our existing, internationally-competitive expertise and cutting-edge research capabilities in core areas and address key common technology gaps.
  • Sustainability: deliver a focused skills and career development network to ensure that we both grow and future-proof the sector and attract foreign investment to the region.

THE FUTURE MEDICINES INSTITUTE 

The Future Medicines Institute (FMI) will drive regional economic growth, create jobs highly-skilled jobs within Northern Ireland Life and Health Sciences sector and ultimately deliver solutions to enhance patient outcomes globally.

The FMI will “level up” Northern Ireland’s Life and Health Sciences sector by enabling development of a cohesive research culture within the region, empowering companies to drive and advance their own research agenda and collaborate and co-evolve by learning from each other. The institute will also act as a hub to foster interactions between companies and clinicians, academics, entrepreneurs and patients.

Strategically located in an existing state-of-the-art research building (Queen’s University's Health Sciences Building) adjacent to leading medical research Centres at Queen’s and the Belfast City Hospital (a University teaching hospital; Belfast Health and Social Care Trust), the FMI will become the focal point for consortium members, international commercial companies, regional SMEs and start-ups across Northern Ireland.

STRENGTH IN PLACES FUND

NIPBT have progressed to the later stages of UK Research and Innovation’s Strength in Places Fund, which is aimed at driving economic growth in specific areas of the UK and enhancing local collaborations involving research and innovation. The consortium were awarded seed corn funding of £50,000 which was utilised to develop a bid competing for a share of a £236 million fund with projects from across the UK.

Learn More

If you would like to learn more about the NIPBT or The Future Medicines Institute get in touch with our team at businessalliance@qub.ac.uk